Navigation Links
InterMune to Release Second Quarter Financial Results on August 6
Date:7/28/2014

BRISBANE, Calif., July 28, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its second quarter 2014 financial results at the close of the U.S. markets on Wednesday, August 6, 2014. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

Interested investors and others may participate in the conference call by dialing 800-728-2056 (U.S.) or +1 212-231-2900 (international), conference ID#21728775. A replay of the webcast and teleconference will be available on the company's website approximately three hours after the call. To access the live webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A telephonic replay will be available for 10 business days following the call and can be accessed by dialing 800-633-8284 (U.S.) or +1 402-977-9140 (international), and entering the conference ID#21728775. 

About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Pirfenidone is approved for marketing by InterMune in the EU and Canada as Esbriet®.  Pirfenidone is not approved for marketing in the United States. InterMune resubmitted the pirfenidone New Drug Application (NDA) to the U.S. FDA on May 23, 2014, to support regulatory registration in the United States. The resubmission has been accepted by the FDA and assigned a target PDUFA date of November 23, 2014. The FDA has granted pirfenidone Breakthrough Therapy Designation. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com/http://www.intermune.com/www.intermune.com.

Logo - http://photos.prnewswire.com/prnh/20120827/SF62570LOGO


'/>"/>
SOURCE InterMune, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
2. InterMune to Present at J. P. Morgan Healthcare Conference
3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
4. InterMune To Present At JMP Securities Healthcare Conference
5. InterMune To Release Third Quarter Financial Results On November 7
6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
7. InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
8. InterMune To Release First Quarter Financial Results On April 24
9. InterMune Reports First Quarter 2013 Financial Results and Business Highlights
10. Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.
11. Andrew Powell Joins InterMune As Executive Vice President And General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 ... ... the commercial launch of flexible packaging for their exceptionally efficient human mesenchymal ... system extends RoosterBio’s portfolio of bioprocess media products engineered to radically streamline ...
(Date:12/8/2016)... 2016  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... developing and commercializing products to treat rare diseases ... today the long-term follow-up data from its Phase ... Innate Defense Regulator (IDR), in the treatment of ... patients undergoing chemoradiation therapy (CRT).  The additional 12-month ...
(Date:12/8/2016)... Savannah River Remediation LLC group evaluated ... NT-MAX Lake & Pond Sludge and Muck ... conjunction with Hexa Armor/ Rhombo cover manufactured by ... Discharge Elimination System requirements. The Savannah ... of elevated pH levels, above 8.5, especially during ...
(Date:12/8/2016)... 2016   Biocept, Inc . (NASDAQ: ... clinically actionable liquid biopsy tests to improve the ... featuring its Target Selector™ Circulating Tumor Cell platform ... detection of actionable biomarkers in patients with metastatic ... Sara Cannon Research Institute (SCRI), the research arm ...
Breaking Biology Technology:
(Date:12/2/2016)... 2016   SoftServe , a global digital ... an electrocardiogram (ECG) biosensor analysis system for continuous ... asset. The smart system ensures device-to-device communication between ... and mobile devices to easily ,recognize, and monitor ... vehicle technology advances, so too must the security ...
(Date:11/29/2016)... 29, 2016   Neurotechnology , a ... recognition technologies, today released FingerCell 3.0, a ... solutions that run on low-power, low-memory microcontrollers. ... less than 128KB of memory, enabling it ... have limited on-board resources, such as: mobile ...
(Date:11/22/2016)... India , November 22, 2016 According to ... (Fingerprint, IRIS, Palm Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and ... 2022", published by MarketsandMarkets, the market is expected to grow from USD ... a CAGR of 16.79% between 2016 and 2022. ... ...
Breaking Biology News(10 mins):